Awakn Life Sciences Corp., a biotechnology company, engages in the researching, developing, operations, and delivering of psychedelic therapeutics to treat addiction and other mental health conditions in the United Kingdom and Europe. The company has a collaboration agreement with the University of Exeter for exploring the use of ketamine-assisted therapy to treat Severe AUD. Awakn Life Sciences Corp. is headquartered in Toronto, Canada.
Stock data | 2024 | Change |
---|---|---|
Price | $0.06 | N/A |
Market Cap | $2.32M | N/A |
Shares Outstanding | 38.59M | N/A |
Employees | 44.00 | N/A |